Jack Elands, Emergence Therapeutics CEO
December 7, 2021 10:20 AM ESTUpdated 10:43 AM
Financing

Can a new Eu­ro­pean biotech make an ADC bet­ter than Pad­cev? In­vestors are putting up al­most $100M to find out

Max Gelman

Senior Editor

A new Eu­ro­pean biotech has put to­geth­er a near­ly $100 mil­lion Se­ries A, and its lead pro­gram is go­ing af­ter a tar­get re­cent­ly val­i­dat­ed by …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

Bio­haven's myo­statin in­hibitor miss­es pri­ma­ry end­point in spinal mus­cu­lar at­ro­phy tri­al

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Gilead buys ex­per­i­men­tal HIV vac­cines from a small Barcelona biotech

A service from the Financial Times